



IFW

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 8, 2004
Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Brewer, Merajver and Coucouvanis

Serial No.: 10/625,839

Filed: July 23, 2003

For: Tetrapropylammonium Tetrathiomolybdate
and Related Compounds for Anti-
Angiogenic Therapies

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: 4100.003200

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. As the filing date of the present application is after June 30, 2003, copies of U.S. patents are no longer required by 37 C.F.R. § 1.98(a)(2) and copies of the listed U.S. patents are not included herewith.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are due in connection with the filing of this Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C., Deposit Account No. 50-0786/4100.003200.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas 77042
(713) 934-7000

Date: October 8, 2004

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
4100.003200Serial No.
10/625,839Applicants
George J. Brewer, Sofia D. Merajver and Dimitri
CoucouvanisFiling Date:
July 23, 2002Group:
1614U.S. Patent Documents
*See Page 1 and 2*Foreign Patent Documents
*See Page 2*Other Art
See Pages 2 - 14

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,762,705	08/09/88	Rubin	424	85	
	A2	5,057,302	10/15/91	Johnson <i>et al.</i>	424	1.1	
	A3	5,100,885	03/31/92	Abrams <i>et al.</i>	514	184	
	A4	5,169,858	12/08/92	Rubin	514	365	
	A5	5,385,933	01/31/95	Rabinovitz <i>et al.</i>	514	499	
	A6	5,563,132	10/08/96	Bodaness	514	185	
	A7	5,697,902	12/16/97	Goldenberg	604	49	
	A8	5,565,491	10/15/96	Schieven	514	492	
	A9	5,512,559	04/30/96	Skalkos <i>et al.</i>	514	185	
	A10	5,443,816	08/22/95	Zamora <i>et al.</i>	424	1.69	
	A11	5,391,547	02/21/95	Cole <i>et al.</i>	514	184	
	A12	4,952,607	08/28/90	Sorenson <i>et al.</i>	514	589	
	A13	4,766,226	08/23/88	Hill <i>et al.</i>	556	18	
	A14	4,678,667	07/07/87	Meares <i>et al.</i>	424	85	
	A15	RE 35,458	02/18/97	Azuara	556	116	
	A16	5,112,598	05/12/92	Biesalski	424	46	
	A17	5,527,533	06/18/96	Tso <i>et al.</i>	424	422	
	A18	5,556,611	09/17/96	Biesalski	424	46	
	A19	5,583,153	12/10/96	Brahn	514	449	
	A20	5,970,974	10/26/99	van der Linden <i>et al.</i>	128	200.16	

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2 - 14</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A21	5,954,047	09/21/99	Armer <i>et al.</i>	128	200.23	
	A22	5,950,619	09/14/99	van der Linden <i>et al.</i>	128	200.16	
	A23	5,698,155	12/16/97	Grosswald <i>et al.</i>	264	402	
	A24	5,639,725	06/17/97	O'Reilly <i>et al.</i>	514	12	
	A25	4,765,539	08/23/88	Noakes <i>et al.</i>	239	3	
	A26	3,916,899	11/04/75	Theeuwes <i>et al.</i>	128	260	
	A27	3,845,770	11/05/74	Theeuwes <i>et al.</i>	128	260	
	A28	4,604,278	08/05/86	Reilly <i>et al.</i>	423	517	
	A29	4,343,746	08/10/82	Anglin <i>et al.</i>	556	57	
	A30	2,909,541	10/20/59	Hugel	260	429	
	A31	6,703,050	03/09/04	Brewer <i>et al.</i>	424	641	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 1 107 795 B1	Nov. 27, 2002	EP			
	B2	EP 1 234 585 A2	Aug. 28, 2002	EP			
	B3	WO 00/13712	Mar. 16, 2000	PCT			
	B4	WO 2004/009072	Jan. 29, 2004	PCT			

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
	Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2 - 14</i>

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Allen and Solomons, "Normal Intestinal Mechanisms in the Absorption of Copper," In: Absorption and Malabsorption of Mineral Nutrients, Solomons and Rosenberg, Eds., Alan R. Liss, Inc., New York, 12:199-229, 1984.
	C2	Alpem-Elran and Brem, "Angiogenesis in Human Brain Tumors: Inhibition by Copper Depletion," <i>Neurological Surgery</i> , pp. 498-500, publication date unknown.
	C3	Brem <i>et al.</i> , "Anticopper Treatment Inhibits Pseudopodial Protrusion and the Invasive Spread of 9L Gliosarcoma Cells in the Rat Brain," <i>Neurosurgery</i> , 26:391-396, 1990.
	C4	Brem <i>et al.</i> , "Inhibition of Angiogenesis and Tumor Growth in the Brain. Suppression of Endothelial Cell Turnover by Penicillamine and the Depletion of Copper, an Angiogenic Cofactor," <i>Am. J. Pathol.</i> , 137(5):1121-1142, 1990.
	C5	Brem <i>et al.</i> , "Tetrathiomolybdate, A Chelator of Copper, Reduces Intracerebral Peritumoral Edema in Rats," <i>Proc. Amer. Assoc. Cancer Res.</i> , 33:76, Abstract 455, 1992.
	C6	Bremner <i>et al.</i> , "Copper Metabolism in Rats Given di-or trithiomolybdates," <i>J. Inorg. Biochem.</i> , 16: 109, 1982.
	C7	Brewer and Yuzbasiyan-Gurkan, "Wilson Disease," <i>Medicine</i> , 71(3):139-164, 1992.
	C8	Brewer and Yuzbasiyan-Gurkan, "Wilson's Disease," In: Textbook of Clinical Neuropharmacology and Therapeutics, 2nd Edition, Klawans <i>et al.</i> , Eds., Raven Press, New York, pp. 191-205, 1992.
	C9	Brewer and Yuzbasiyan-Gurkan, "Wilson's Disease: An Update, with Emphasis on New Approaches to Treatment," <i>Dig. Dis.</i> , 7(4):178-193, 1989.
	C10	Brewer, "Interactions of Zinc and Molybdenum With Copper in Therapy of Wilson's Disease," <i>Nutr.</i> , 11(1 Suppl):114-116, 1995.
	C11	Brewer, "Practical Recommendations and New Therapies for Wilson's Disease," <i>Drugs</i> , 50(2):240-249, 1995.
	C12	Brewer, "Thiomolybdates in the Treatment of Wilson's Disease," <i>Arch. Neurol.</i> , 49:132-133, 1992.
	C13	Brewer, "Zinc in the Treatment of Wilson's Disease," <i>Nutrition and the MD.</i> 19(12), 1993.
	C14	Brewer <i>et al.</i> , "Treatment of Wilson's disease with Ammonium Tetrathiomolybdate. I Initial Therapy in 17 Neurologically Affected Patients," <i>Arch. Neurol.</i> , 51(6):545-554, 1994.
	C15	Brewer <i>et al.</i> , "Use of Zinc Acetate to Treat Copper Toxicosis in Dogs," <i>JAVMA</i> , 201:564-568, 1992.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvannis	
	Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc XIII: Therapy with Zinc in Presymptomatic Patients from the Time of Diagnosis," <i>J. Lab. Clin. Med.</i> , 123:849-858, 1994.
	C17	Brewer <i>et al.</i> , "Initial therapy of Wilson's Disease Patients with Tetrathiomolybdate," <i>Arch. Neurol.</i> , 48(1):42-47, 1991.
	C18	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc III. Prevention of Reaccumulation of Hepatic Copper," <i>J. Lab. Clin. Med.</i> , 109:526-531, 1987.
	C19	Brewer <i>et al.</i> , "Oral Zinc Therapy for Wilson's Disease," <i>Annals. Int. Med.</i> , 99:314-320, 1983.
	C20	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc: IV. Efficacy Monitoring Using Urine and Plasma Copper," <i>Proc. Soc. Exper. Biol. Med.</i> , 184:446-455, 1987.
	C21	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Ammonium Tetrathiomolybdate II. Initial Therapy in 33 Neurologically Affected Patients and Follow-up on Zinc Therapy," <i>Arch. Neurol.</i> , 53:1017-1025, 1996.
	C22	Brewer <i>et al.</i> , "The Use of ⁶⁴ Copper Measurements to Diagnose Canine Copper Toxicosis," <i>J. Vet. Int. Med.</i> , 6:41-43, 1992.
	C23	Brewer <i>et al.</i> , "Worsening of Neurological Syndrome Upon Initial Treatment of Wilson's Disease Patients with Penicillamine," <i>Arch. Neurol.</i> , 44:490-493, 1987.
	C24	Brewer <i>et al.</i> , "Development of Neurologic Symptoms in a Patient with Asymptomatic Wilson's Disease Treated with Penicillamine," <i>Arch. Neurol.</i> , 51:304-305, 1994.
	C25	Brewer <i>et al.</i> , "Zinc Therapy of Wilson's Disease VIII. Dose Response Studies," <i>J. Trace Elem. Exp. Med.</i> , 3:227-234, 1990.
	C26	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc: IX. Response of Serum Lipids," <i>J. Lab. Clin. Med.</i> , 118:466-470, 1991.
	C27	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc XI. Interaction with Other Anticopper Agents," <i>J. Amer. Coll. Nut.</i> , 12(1):26-30, 1993.
	C28	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc XII. Dose Regimen Requirements," <i>Amer. J. Med Sci.</i> , 305(4):199-202; 1993.
	C29	Brewer <i>et al.</i> , "Molecular Genetics and Zinc-Copper Interactions in Human Wilson's Disease and Canine Copper Toxicosis," In: Essential and Toxic Trace Elements in Human Health and Disease: An Update, Prasad, Ed., Allan R. Liss, New York, PCBR 380:129-145, 1993.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C30	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc VI. Initial Treatment Studies," <i>J. Lab. Clin. Med.</i> , 114: 633-638, 1989.
	C31	Brewer <i>et al.</i> , "Treatment of Wilson's Disease," <i>Sem. Neural.</i> , 7:209-220, 1987.
	C32	Coucouvanis <i>et al.</i> , "An Inorganic Functional Group Approach to the Systematic Synthesis and Reactivity Studies of Binuclear Mo/S and Mo/S/O Complexes," <i>Polyhedron</i> , 8(13/14):1705-1716, 1989.
	C33	Coucouvanis <i>et al.</i> , "Dinuclear Fe-Mo-S Complexes Containing the FeS ₂ Mo Core. Syntheses, Ground-State Electronic Structures, and Crystal and Molecular Structures of the [(C ₆ H ₅) ₄ P] ₂ [C ₆ H ₅ S] ₂ FeS ₂ MoS ₂], [(C ₂ H ₅) ₄ N] ₂ [(C ₆ H ₅ S) ₂ FeS ₂ WS ₂], and [(C ₆ H ₅) ₄ P] ₂ [(S) ₃ FeS ₂ MS ₂] (M = Mo, W) Complexes," <i>Inorg. Chem.</i> , 22:293-308, 1983.
	C34	Coucouvanis <i>et al.</i> , "Heterodinuclear Di-μ-Sulfido Bridged Dimers Containing Iron and Molybdenum or Tungsten. Structures of (PhP) ₂ (FeMS ₉) Complexes (M = Mo, W)," <i>J. Am. Chem. Soc.</i> , 102:1730-1732, 1980.
	C35	Coucouvanis <i>et al.</i> , "Successful Isolation of a Reduced Tetrathiometalate Complex. Synthesis and Structural Characterization of the [(MoS ₄) ₂ Fe] ³⁻ Trianion," <i>J. Am. Chem. Soc.</i> , 102:6644-6646, 1980.
	C36	Coucouvanis <i>et al.</i> , "Synthesis and Structural Characterization of [(No) ₂ FeS ₂ MoS ₂] ²⁻ A Dinitrosyl Complex Containing the FeS ₂ MoS ₂ Core," <i>Inorg. Chim. Acta</i> , 53:L135-L137, 1981.
	C37	Coucouvanis <i>et al.</i> , "Synthesis of Thiomolybdenyl Complexes with [Mo ₂ (S) ₂ (O) ₂] ²⁺ Cores and Substitutionally Labile Ligands. Crystal and Molecular Structure of the [Mo ₂ O ₂ S ₄ (DMF) ₃] Complex," <i>Inorg. Chem.</i> , 27:3272-3273, 1988.
	C38	Coucouvanis <i>et al.</i> , "Trinuclear Fe-M-S Complexes Containing a Linear Fe-M-Fe Array and a Bridging S ₂ MS ₂ Unit. Electronic Structures and Crystal and Molecular Structures of the [(C ₆ H ₅) ₄ P] ₂ [Cl ₂ FeS ₂ MS ₂ FeCl ₂] (M = Mo, W) Complexes," <i>Inorg. Chem.</i> , 23:741-749, 1984.
	C39	Coucouvanis, "Fe-M-S Complexes Derived from MS ₄ ²⁻ Anions (M = Mo, W) and Their Possible Relevance as Analogues for Structural Features in the Mo Site of Nitrogenase," <i>Acc. Chem. Res.</i> , 14:201-209, 1981.
	C40	Coucouvanis, "Syntheses, Structures, and Reactions of Binary and Tertiary Thiomolybdate Complexes Containing the (O)Mo(S _x) and (S)Mo(S _x) Functional Groups (x = 1,2,4)," <i>Adv. Inorg. Chem.</i> , 45:1-73, 1998.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C41	Engleka and Maciag, "Inactivation of Human Fibroblast Growth Factor-1 (FGF- 1) Activity by Interaction with Copper Ions Involves FGF-1 Dimer Formation Induced by Copper-Catalyzed Oxidation," <i>J. Biol. Chem.</i> , 267:11307-11315, 1994.
	C42	Fell <i>et al.</i> , "Gut Pathology of Rats Dosed with Tetrathiomolybdate," <i>J. Corn. Pathol.</i> , 89:495, 1979.
	C43	Folkman, "Angiogenesis," <i>The Journal of Biological Chemistry</i> , 267(16):10931-1 0934, 1992.
	C44	Folkman and Klagsbrun, "Angiogenic Factors," <i>Science</i> , 23:442-447, 1987.
	C45	Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," <i>Nature Med.</i> , 1:27-31, 1995.
	C46	Folkman, "The Influence of Angiogenesis Research on Management of Patients with Breast Cancer," <i>Breast Cancer Res. Treat.</i> , 36(2):109-118, 1995.
	C47	Folkman, "Anti Angiogenic Therapy," In: <i>Cancer: Principles and Practice of Oncology</i> , Lippincott-Raven Publishers, pp. 3075-3085, 1997.
	C48	Gooneratne <i>et al.</i> , "An Investigation of the Effects of Inn Venous Administration of Thiomolybdate on Copper Metabolism in Chronic Cu-Poisoned Sheep," <i>Br. J. Nutr.</i> , 46:469, 1981.
	C49	Gooneratne <i>et al.</i> , "Intravenous Administration of Thiomolybdate for the Prevention and Treatment of Chronic Copper Poisoning in Sheep," <i>Br. J. Nutr.</i> , 46:457, 1981.
	C50	Gross <i>et al.</i> , "Inhibition of Basic Fibroblast Growth Factor-Induced Angiogenesis and Glioma Tumor Growth In Vivo in Copper Depleted Rats," <i>Proc. Amer. Assoc. Cancer Res.</i> , 32:57, Abstract 338, 1991.
	C51	Gullino, "Considerations on the Mechanism of the Angiogenic Response," <i>Anticancer Res.</i> , 6(2):153-158, 1986.
	C52	Hadjikyriacou and Coucouvanis, "New Members of the $[\text{Mo}_2(\text{S})_n(\text{S}_2)_{6-n}]^{2-}$ Series. Synthesis, Structural Characterization, and Properties of the $[\text{Mo}_2\text{S}_9]^{2-}$, $[\text{Mo}_2\text{S}_7]^{2-}$ and $[\text{Mo}_2\text{S}_6]^{2-}$ Thioanions," <i>Inorg. Chem.</i> , 26:2400-2408, 1987.
	C53	Hill <i>et al.</i> , "Treatment of Wilson's Disease with Zinc II. Validation of Oral ^{64}Cu Copper Uptake with Copper Balance," <i>Am. J. Med. Sci.</i> , 12:344, 1986.
	C54	Hill <i>et al.</i> , "Treatment of Wilson's Disease with Zinc, I: Oral Zinc Therapy Regimens," <i>Hepatology</i> , 7:522-528, 1987.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Att. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2 - 14</i>	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	Hourani and Demopoulos, "Inhibition of S-91 Mouse Melanoma Metastases and Growth by D-Penicillamine," <i>Laboratory Investigation</i> , 21(5):434-438, 1969.
	C56	Kanatzidis and Coucouvanis, "Structure of Bis(tetraethylammonium) Tetrathiomolybdate(VI), $2C_8H_{20}N^+MoS_4^{2-}$," <i>Acta Cryst.</i> , C39:835-838, 1983.
	C57	Lee <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc VII. Protection of the Liver for Copper Toxicity by Zinc Induced Metallothionein in a Rat Model," <i>J. Lab. Clin. Med.</i> , 114:639-645, 1989.
	C58	Marshall <i>et al.</i> , "Phase I Trial of Orally Administered Pentosan Polysulfate in Patients with Advanced Cancer," <i>Clin. Cancer Res.</i> , 3:2347-2354, 1997.
	C59	Merajver <i>et al.</i> , "Copper Depletion as an Anti-Angiogenic Strategy in HER2-neu Transgenic Mice," Proceedings of Special AACR Conference on Angiogenesis and Cancer, Abstract #B-II, January 22-24, 1998.
	C60	Merajver, "Phase I Study of Tetrathiomolybdate in Metastatic Cancer," NIH Grant No. 5R03CA77122-02.
	C61	Mills <i>et al.</i> , "Effects of Molybdate, Sulfide, and Tetrathiomolybdate on Copper Metabolism in Rats," <i>J. Inorg. Biochem.</i> , 14:189, 1981.
	C62	Mills <i>et al.</i> , "Copper and Molybdenum Absorption by Rats Given Ammonium Tetrathiomolybdate," <i>J. Inorg. Biochem.</i> , 14: 163, 1981.
	C63	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea," <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C64	Patstone and Maher, "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271 :3343-3346, 1996.
	C65	Raju <i>et al.</i> , Ceruloplasmin, Copper Ions, and Angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:1183-1188, 1982.
	C66	Schapira and Schapira, "Use of Ceruloplasmin Levels to Monitor Response to Therapy and Predict Recurrence of Breast Cancer," <i>Breast Cancer Res. Treat.</i> , 3:223-224, 1983.
	C67	Schuschke <i>et al.</i> , "Short-Term Dietary Copper Deficiency does not Inhibit Angiogenesis in Tumours Implanted in Striated Muscle," <i>Br. J. Cancer</i> , 66:1059-1064, 1992.
	C68	Shing, "Heparin-Copper Biaffinity Chromatography of Fibroblast Growth Factors," <i>J. Biol. Chem.</i> , 263:9059-9062, 1988.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
	Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2 - 14</i>

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C69	Teo <i>et al.</i> , "Mo, W, and Fe EXAFS of the $[Cl_2FeS_2MS_2FeCl_2]^{2-}$ (M = Mo, W) Dianions. A Comparison with the Mo EXAFS of Nitrogenase," <i>J. Am. Chem. Soc.</i> , 105:5767-5770, 1983.
	C70	Yoshida <i>et al.</i> , "Copper Chelation Inhibits Tumor Angiogenesis in the Experimental 9L Gliosarcoma Model," <i>Neurosurgery</i> , 37(2):287-292, 1995.
	C71	Yoshida <i>et al.</i> , "Suppression of 9L Gliosarcoma Growth by Copper Depletion with Copper-Deficient Diet and D-Penicillamine," <i>J. Neurooncol.</i> , 17(2):91-97, 1993.
	C72	Yuzbasiyan-Gurkan <i>et al.</i> , "Treatment of Wilson's Disease with Zinc V. Changes in Serum Levels of Lipase, Amylase and Alkaline Phosphatase in Wilson's Disease Patients," <i>J. Lab. Clin. Med.</i> , 114:520-526, 1989.
	C73	Yuzbasiyan-Gurkan <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc X. Intestinal Metallothionein Induction," <i>J. Lab. Clin. Med.</i> , 120:380-386, 1992.
	C74	Zagzag, "The effects of Copper Depletion on Intracerebral Angiogenesis and Growth of Experimental Brain Tumors," <i>Dissertation Abstracts International</i> , 53(12B):6160, 1988.
	C75	Ziche <i>et al.</i> , "Role of Prostaglandin E1 and Copper in Angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:475-482, 1982.
	C76	Brem "Angiogenesis and Cancer Control: From Concept to Therapeutic Trail," <i>Cancer Control</i> , 6(5):436-458, 1999.
	C77	Brewer and Merajver, "Treatment of Metastatic Cancer with the Anticopper Antiangiogenic Drug Tetrathiomolybdate," <i>J. Invest. Med.</i> , 47(7):223A, 1999.
	C78	Brewer <i>et al.</i> , "Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study," <i>Clin. Canc. Res.</i> , 6(1):1-10, 2000.
	C79	International Search Report dated July 4, 2000 (PCT/US99/20374; 4100.001010).
	C80	Merajver, "A Phase I study of Oral Tetrathiomolybdate (TM) as a Decoppering and Anti-Angiogenesis Agent for Metastatic Cancer," From the Internet at website http://www.cancer.med.umich.edu/cgi-bin/protocol?9708_701 , 1998.
	C81	Sergeant and Johnson, "Iron and Copper Requirements for Proliferation and Differentiation of a Human Promyelocytic Leukemia Cell Line (HL-60)," <i>J. Cell. Physiol.</i> , 163:477-485, 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C82	Shah <i>et al.</i> , "Circular Dichroism of Carbohydrate-Molybdate Complexes," <i>Stud. Nat. Prod. Chem.</i> , 15:423-438, 1995.
	C83	Benjamin <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
	C84	Borgstrom <i>et al.</i> , "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>In Vivo</i> ," <i>The Prostate</i> , 35:1-10, 1998.
	C85	Jeannin <i>et al.</i> , "Molecular Architecture of Copper(1) Thiometallate Complexes. Examples of a Cubane with an Extra Face, (NPr ₄) ₃ [MS ₄ Cu ₄ Cl ₅]," <i>Inorganic. Chimica. Acta.</i> , 198-200:493-500, 1992.
	C86	Malavé <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngenic Mice," <i>J. Natl. Cancer Inst.</i> , 62(1):83-88, 1979.
	C87	Passaniti <i>et al.</i> , "Methods in Laboratory Investigation," <i>Laboratory Investigation</i> , 67(4):519-528, 1992.
	C88	Sécheresse <i>et al.</i> , "Heterobimetallic Aggregates of Copper(1) with Thio-tungstate and -molybdate. Cation Effect in Aggregation of Ms ₄ Cu ₄ Cl ₅ Units, a Crystallographic Study," <i>J. Chem. Soc. Dalton Trans.</i> , 11:2875-2881, 1991.
	C89	Sugiura <i>et al.</i> , "Studies in a Tumor Spectrum," <i>Cancer Research</i> , 15:38-51, 1955.
	C90	Takai <i>et al.</i> , "Preparation, Structure and Properties of Mixed-Metal Trinuclear Complex: (Pr ₄ N) ₂ [MoO(WS ₄) ₂]," <i>Chemistry Letters</i> , 8:645-646, 1996.
	C91	Bajou <i>et al.</i> , "Absence of Host Plasminogen Activator Inhibitor I Prevents Cancer Invasion and Vascularization," <i>Nat. Med.</i> , 4:923-928, 1998.
	C92	Bamba <i>et al.</i> , "Release Mechanisms in Gel Forming Sustained Release Preparations," <i>Int. J. Pharm.</i> , 2:307, 1979.
	C93	Blood <i>et al.</i> , "Tumor Interactions With the Vasculature: Angiogenesis and Tumor Metastasis," <i>Biochim. Biophys. Acta.</i> , 1032:89-118, 1990.
	C94	Brown, "Metal Toxicity and Therapeutic Intervention," <i>Biochem. Soc. Trans.</i> , 30:742- 745 2002.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
	Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C95	Brown, "Copper and Prion Disease," <i>Brain Res. Bull.</i> , 55:165-173, 2001.
	C96	Carri <i>et al.</i> , "Copper-Dependent Oxidative Stress, Alteration of Signal Transduction and Neurodegeneration in Amyothophic Lateral Sclerosis," <i>Funct. Neurol.</i> , 16:181-188, 2001.
	C97	Chakravarty <i>et al.</i> , "Serum Copper in Malignant Neoplasia with Special Reference to the Cervix Uteri," <i>J. Cancer Res. Clin. Oncol.</i> , 108: 312-315, 1984.
	C98	Chambers <i>et al.</i> , "Macrophage Colony-Stimulating Factor Mediates Invasion of Ovarian Cancer Cells Through Urokinase," <i>Cancer Research</i> , 55:1578-1585, 1995.
	C99	Chen <i>et al.</i> , "TNF-RI Signaling: A Beautiful Pathway," <i>Science</i> , 296:1634-1635, 2002.
	C100	Crowley <i>et al.</i> , "Prevention of Metastasis by Inhibition of the Urokinase Receptor," <i>Proc. Nat'l. Acad. Sci. USA</i> , 90:5021-5025, 1993.
	C101	During <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant; In vivo Characterization," <i>Ann. Neurol.</i> , 25:351-356, 1989.
	C102	Folkman, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," <i>Ann. Surg.</i> , 175: 409-416, 1972.
	C103	Folkman, "Angiogenesis Inhibitors Generated by Tumors," <i>Mol. Med.</i> , 1(2):120-122 1995.
	C104	Gnjec <i>et al.</i> , "Transition Metal Chelator Therapy - A potential Treatment For Alzheimer's Disease?" <i>Front Biosci.</i> , 16-23, 2002.
	C105	Goodson, "Medical Applications of Controlled Release" 2:115-138, 1984.
	C106	Gorelik <i>et al.</i> , "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," <i>J. Nat'l. Cancer Inst.</i> , 65: 1257-1264, 1980.
	C107	Gorelik, <i>et al.</i> , "Host's Immune State and Kinetics of Local Tumor Growth Control- Progression of Postoperative Lung Metastasis," <i>Rec. Results Cancer Res.</i> , 75:20-28, 1980.
	C108	Hanada <i>et al.</i> , "Regulation of Cytokine Signaling and Inflammation," <i>Cytokine Growth Factor Rev.</i> , 13: 413-421, 2002.
	C109	Hanahan <i>et al.</i> , "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):353-364, 1996.
	C110	Hilgard <i>et al.</i> , "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," <i>Br. J. Cancer</i> , 35:78-86, 1977.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C111	Howard <i>et al.</i> , "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," <i>J. Neurosurg.</i> , 71:105-112, 1989.
	C112	Isakov <i>et al.</i> , "An Immune Response Against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," <i>Invasion Metas.</i> , 2:12-32, 1982.
	C113	Kleinman <i>et al.</i> , "Basement Membrane Complexes with Biological Activity," <i>Biochem.</i> , 25: 312-318, 1986.
	C114	Koch <i>et al.</i> , "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis," <i>Science</i> , 258:1798-1801, 1992.
	C115	Kowalik-Jankowska <i>et al.</i> , "Possible Involvement of Copper (II) in Alzheimer Disease," <i>Environ. Health Perspect.</i> , 5:869-870, 2002.
	C116	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem.</i> , 23:61-126, 1983.
	C117	Langer, "New Methods of Drug Delivery," <i>Science</i> , 249:1527-1533, 1990.
	C118	Levy <i>et al.</i> , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> , 228:190-192, 1985.
	C119	Llanos <i>et al.</i> , "The Molecular Basis of Copper Homeostasis and Copper-Related Disorders," <i>DNA Cell Biol.</i> , 21:259-270, 2002.
	C120	Loskutoff <i>et al.</i> , "A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM," <i>Ann. N.Y. Acad. Sci.</i> , 902:272-282, 2000.
	C121	Malave <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," <i>J. Nat'l. Cancer Inst.</i> , 62:83-88, 1979.
	C122	Mandinov <i>et al.</i> , "Copper Chelation Represses the Vascular Response To Injury" <i>PNAS</i> , 100:6700-6705, 2003.
	C123	Maynard <i>et al.</i> , "Overexpression of Alzheimer's Disease Amyloid- β Opposes the Age-Dependent Elevations of Brain Copper and Iron," <i>J. Biol. Chem.</i> , 277(47):44670-44676, 2002.
	C124	Millauer <i>et al.</i> , "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>In vivo</i> ," <i>Cancer Res.</i> 56:1615-1620, 1996.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C125	Min <i>et al.</i> , "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> , 56:2428-2433, 1996.
	C126	Miyake <i>et al.</i> , "Transforming Growth Factor- β 1 Stimulates Contraction of Human Glioblastoma Cell-Mediated Collagen Lattice Through Enhanced α 2 Integrin Expression," <i>J. Neuropathol. Exp. Neurol.</i> , 59:18-28, 2000.
	C127	Nguyen <i>et al.</i> , "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," <i>Microvascular Res.</i> , 47:31-40, 1994.
	C128	Odedra <i>et al.</i> , "Low Molecular Weight Angiogenesis Factors," <i>Pharmac. Ther.</i> , 49:111-124, 1991.
	C129	Osawa <i>et al.</i> , "Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF-kB and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes," <i>Infect. Immun.</i> , 70:6294-6301, 2002.
	C130	Pan <i>et al.</i> , "Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis," <i>Cancer Res.</i> , 62: 4854-4859, 2002.
	C131	Parish <i>et al.</i> , "A Basement-Membrane Permeability Assay Which Correlates with the Metastatic Potential of Tumor Cells," <i>Int. J. Cancer</i> , 52:378-383, 1992.
	C132	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea" <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C133	Passaniti <i>et al.</i> , "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Lab. Invest.</i> , 67:519-528, 1992.
	C134	Patstone <i>et al.</i> , "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271(7):3343-3346, 1996.
	C135	Perry <i>et al.</i> , "The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders," <i>CNS Drugs</i> , 16:339-352, 2002.
	C136	Rabbani <i>et al.</i> , "Prevention of Prostate-Cancer Metastasis <i>In Vivo</i> By a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)," <i>Int. J. Cancer</i> , 63:840-845, 1995.
	C137	Redman <i>et al.</i> , "Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer," <i>Clin. Cancer Res.</i> , 9:1666-1672, 1996.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
	Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C138	Rupnick <i>et al.</i> , "Adipose Tissue Mass Can Be Regulated Through the Vasculature," <i>Proc. Natl. Acad. Sci.</i> , 99:10730-10735, 2002.
	C139	Saudek <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 321:574, 1989.
	C140	Schnaper <i>et al.</i> , "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> , 165:107-118, 1995.
	C141	Sefton, "Implantable Pumps," <i>CRC Crit. Rev. Biomed. Eng.</i> , 14(3):201-240, 1987.
	C142	Sen <i>et al.</i> , "Copper-Induced Vascular Endothelial Growth Factor Expression and Wound Healing," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:H1821-H1827, 2002.
	C143	Shockley <i>et al.</i> , "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," <i>Ann. N.Y. Acad. Sci.</i> , 617:367-382, 1991.
	C144	Strausak <i>et al.</i> , "Copper in Disorders with Neurological Symptoms: Alzheimer's, Menkes, and Wilson Diseases," <i>Brain Res. Bull.</i> , 55:175-185, 2001.
	C145	Talmadge <i>et al.</i> , "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," <i>J. Nat'l. Cancer Inst.</i> , 69:975-980, 1982
	C146	Thakur <i>et al.</i> , "Indium-111-Labeled Leukocytes for the Localization of Abscesses: Preparation, Analysis, Tissue Distribution, and Comparison with Gallium-67 Citrate in Dogs," <i>J. Lab. Clin. Med.</i> , 89:217-228, 1977.
	C147	Treat <i>et al.</i> , in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, 353-365, 1989.
	C148	Van Golen <i>et al.</i> , "Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma," <i>Neoplasia</i> , 4(5):373-379, 2002.
	C149	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Develop. Indus. Pharm.</i> , 26(7):695-708, 2000.
	C150	Verschoye <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> , 80, Suppl. 2, 96, 1999.
	C151	Volpert <i>et al.</i> , "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," <i>J. Clin. Invest.</i> , 98:671-679, 1996.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvani	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2 - 14</i>	

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C152	Xing <i>et al.</i> , "Overexpression of Urokinase Receptor in Breast Cancer Cells Results in Increased Tumor Invasion, Growth and Metastasis," <i>Int. J. Cancer</i> , 67:423-429, 1996.
	C153	International Search Report for PCT/US03/003210, mailed December 18, 2003 (4100.003210).
	C154	International Search Report for PCT/US03/23031, mailed June 29, 2004

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.